Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

More than 500,000 people in the UK are now on the drugs and could lose between 15-20% of their weight in just a few months.

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

More than 500,000 people in the UK are now taking weight-loss injections, with the majority coming from private pharmacies.

HealthDay News — Racial and ethnic disparities are seen in the use of obesity-management medications, according to a study published online Dec. 17 in the Journal of Racial and Ethnic Health ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Queen Mary University of London has launched a new spinout company, Elcella, founded by Dr Madusha Peiris and Dr Rubina Aktar ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...